A minimal anonymized data set necessary to replicate our study findings has been added to the Supporting Information.

Introduction {#sec004}
============

Cardiometabolic disease is the leading cause of death in women worldwide. In the United States, cardiometabolic diseases are responsible for more than 25% of mortality in women \[[@pone.0190662.ref001]\]. In the last forty years, the global age standardized prevalence of obesity in women, as one of the major modifiable risk factors for cardiometabolic diseases, has more than doubled; from 6.4% (5.1 to 7.8) in 1975 to 14.9% (13.6 to 16.1) in 2014 \[[@pone.0190662.ref002]\]. The prevalence of obesity among women of childbearing age is even higher: 16.4% in 2009. Obesity reduces fertility \[[@pone.0190662.ref003], [@pone.0190662.ref004]\] and increases the risk of atherosclerosis, hypertension, dyslipidemia, chronic inflammation, and insulin resistance \[[@pone.0190662.ref005], [@pone.0190662.ref006]\]. The clustering of these cardiometabolic risk factors is known as metabolic syndrome (MetS) \[[@pone.0190662.ref007], [@pone.0190662.ref008]\]. In women, MetS doubles the risk of cardiovascular mortality \[[@pone.0190662.ref009], [@pone.0190662.ref010]\]. Both cardiometabolic and reproductive morbidity reduce physical and mental quality of life (QoL) \[[@pone.0190662.ref011], [@pone.0190662.ref012]\]. QoL is an important outcome, as it reflects individual perception of both mental and physical wellbeing. Moreover, poor QoL has been linked to an increased risk of all-cause mortality \[[@pone.0190662.ref013]\].

Current international guidelines state that lifestyle improvements are the cornerstone of primary prevention and treatment of obesity and cardiometabolic diseases \[[@pone.0190662.ref014], [@pone.0190662.ref015]\]. Lifestyle improvements are difficult to achieve and the effects on weight reduction and retention are disappointing \[[@pone.0190662.ref016]\]. Despite that lifestyle interventions in patients at risk of type 2 diabetes led to positive effects on cardiometabolic outcomes like Body Mass Index (BMI), waist and hip circumference, fasting plasma glucose levels and blood pressure \[[@pone.0190662.ref017]\]. The success of a lifestyle intervention depends on several factors including intrinsic motivation, but also timing, duration, and intensity of the intervention are important \[[@pone.0190662.ref018], [@pone.0190662.ref019]\]. In general, women are especially receptive to advice about lifestyle before and during pregnancy. For example, 39% of women who are planning a pregnancy discontinue tobacco smoking, which is almost eight times higher than quitting rates in women not planning a pregnancy \[[@pone.0190662.ref020], [@pone.0190662.ref021]\]. Therefore we hypothesized that obese women might benefit from a lifestyle intervention prior to infertility treatment.

The LIFEstyle study is the first large randomized controlled trial (RCT) to investigate the effects of a six month lifestyle intervention among obese infertile women who intended to become pregnant. The effects of the intervention on reproductive outcomes were published in May 2016 \[[@pone.0190662.ref022]\]. Women in the intervention group had significantly more natural conceptions and a comparable rate of ongoing pregnancies, although there was no increased rate of vaginal birth of a healthy singleton at term. Here we report the effects on cardiometabolic health and QoL.

Materials and methods {#sec005}
=====================

Design {#sec006}
------

The LIFEstyle study, a multi-center RCT was conducted in 17 general and six academic medical centers across the Netherlands. Participants were included in the study between June 9, 2009, and June 22, 2012. The study was conducted following the principles of the Declaration of Helsinki and approved by the medical ethics committee of the University Medical Centre Groningen (UMCG) (METc code: 2008/284), as well as by the board of directors of the other participating hospitals (N = 22). All included participants gave written informed consent. The trial was registered in the Netherlands Trial Registry (NTR 1530) and the LIFEstyle study protocol has been published \[[@pone.0190662.ref022], [@pone.0190662.ref023]\].

Participants {#sec007}
------------

Infertile women aged between 18 and 39 years, with a BMI of ≥ 29 kg/m^2^ were eligible. Infertility was defined as chronic anovulation or unsuccessful conception for at least 12 months \[[@pone.0190662.ref024]\]. Women with severe endometriosis, premature ovarian insufficiency, endocrinopathy, untreated preexisting hypertension, or women with a history of hypertension related pregnancy complications were excluded from participating \[[@pone.0190662.ref023]\].

Randomization {#sec008}
-------------

Participants were randomized 1:1 between a six month lifestyle intervention preceding infertility treatment or direct infertility treatment. Stratified randomization according to trial center and ovulatory status was performed at the Academic Medical Centre in Amsterdam with an online program.

Lifestyle intervention {#sec009}
----------------------

The goal of the lifestyle intervention was a 5--10% weight loss or a BMI \< 29 kg/m^2^ within six months. The dietary therapy, using an online diary, aimed at caloric reduction of 600 kcal, with a minimum intake of 1200 kcal/day \[[@pone.0190662.ref025]\]. Participants were advised to be physically active on moderate-intensity level for at least two or three times a week. Daily physical activity was stimulated with the use of a pedometer, aimed at 10.000 steps per day. The individualized behavioral modification was focused on creating awareness of lifestyle predisposing to obesity. The lifestyle intervention was in concordance with the recommendations of the National Institute of Health \[[@pone.0190662.ref026]\].

The lifestyle intervention consisted of face-to-face sessions of approximately 30 minutes at the outpatient clinics, four in the first three months and two in the last three months and four sessions by telephone or e-mail. The intervention coaches had a background in nursing or nutritional science and were trained to practice motivational counselling techniques \[[@pone.0190662.ref027]\]. A structured software program was used to minimize the practice variation between the intervention coaches \[[@pone.0190662.ref028]\].

Participants discontinued the intervention if they became pregnant, but in case of a miscarriage they could re-enter the intervention. Participants who successfully reached the goal of the lifestyle intervention could proceed with their indicated infertility treatment before they had finished the six month intervention \[[@pone.0190662.ref029]\]. If women missed two or more consecutive sessions, they were considered to have not completed the intervention.

Control strategy {#sec010}
----------------

Participants allocated to the control group were treated directly in accordance with Dutch infertility guidelines, irrespective of their BMI \[[@pone.0190662.ref029]\]. Anovulatory women started with ovulation induction with clomiphene citrate. If pregnancy did not occur in six to 12 cycles or if women developed clomiphene resistance, gonadotropin therapy was initiated in a low-dose step-up regimen for a maximum of 12 cycles \[[@pone.0190662.ref030]\]. In ovulatory women, treatment depended on the estimated probability of natural conception according to the Hunault prediction model \[[@pone.0190662.ref031]\]. If the probability was estimated to be \< 30%, women were offered up to six cycles of intrauterine insemination (IUI). If the probability was estimated to be \> 30%, expectant management was proposed for six to12 months. In vitro fertilization was initiated in women with tubal disease or after IUI had failed. Intracytoplasmic sperm injection was used in couples with severe male-factor infertility.

Patient involvement {#sec011}
-------------------

A single center pilot study had been performed previously to evaluate the intervention. During this pilot study, it became clear that patients preferred individual sessions with evaluation of personal goals instead of group sessions, because individual care was considered less time consuming. Otherwise, patients were not involved in the design nor in the conduct of the LIFEstyle study. The Dutch patient support group 'Freya' invited their peers on their website to participate in the trial. Participants received a personal letter with the results of the trial in layman's terms.

Outcome measures {#sec012}
----------------

The prespecified outcomes were weight, BMI (weight in kg divided by height in m^2^), waist- and hip circumference and ratio, systolic and diastolic blood pressure, fasting serum concentrations of glucose and insulin, and physical and mental QoL. Insulin resistance was quantified using the homeostasis model assessment of insulin resistance (HOMA-IR). This model was defined as fasting insulin concentration in μU/mL multiplied by fasting glucose concentration in mmol/L divided by 22.5 \[[@pone.0190662.ref032]\].

Non-prespecified outcomes were fasting serum concentrations of triglycerides, total cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and high sensitive C-reactive protein (hs-CRP). Participants were identified with MetS if they met at least three of the following criteria: (1) glucose ≥5.6 mmol/L; (2) HDL-C \<1.3 mmol/L; (3) triglycerides ≥1.7 mmol/L; (4) waist circumference ≥88 cm or (5) blood pressure ≥130/85 mmHg, based on the 2001 revised criteria of the National Cholesterol Education Program ATP III \[[@pone.0190662.ref008]\].

The power calculation was based on the primary outcome of the LIFEstyle study: the vaginal birth of a healthy singleton at 37 weeks or more within 24 months. This outcome and the power calculations have been published previously \[[@pone.0190662.ref022]\].

Study procedures {#sec013}
----------------

In all non-pregnant participants, during the hospital visits (i.e. at randomization, three and six months), research nurses that were not involved in the lifestyle intervention coaching, measured body weight (kg), height (cm), waist circumference (measured in cm at the narrowest part between the lower rib and iliac crest), hip circumference (measured in cm at the level of the greatest gluteal protuberance), and blood pressure (mmHg, measured manually or electronically in sitting position). Fasting blood samples were collected by venipuncture into one serum and one sodium fluoride vacutainer tube. Serum samples were kept at room temperature for a minimum of 30 minutes for coagulation, and then centrifuged at 1700 x g for 10 minutes at 4°C to obtain serum and plasma, which were stored at -80°C. The biochemical analyses were performed in the central laboratory of the University Medical Centre Groningen after the trial had been completed. Hence, results were unknown to participants and care providers until after trial completion and could not have impacted the participants' management. Hs-CRP was measured with an immuno-turbidimetric assay. Triglycerides, total cholesterol, HDL-C, and LDL-C concentrations were measured using enzymatic colorimetric assays. Fasting plasma glucose was measured with an enzymatic UV test (hexokinase method). All previously described assays were produced by Roche^®^ Modular P (Roche^®^, Manheim, Germany). Insulin was measured with the Architect manufactured by Abbott Diagnostics (Lake Forest, Illinois, United States), using an chemiluminescent micro particle immunoassay. The intra- and interassay variation was respectively 0.5--4.0% and 1.9--6.2% for hs-CRP; 1.5% and 1.8% for triglycerides; 0.8% and 1.7% for total cholesterol; 0.6--0.95% and 1.2--1.3% for HDL-C; 0.72%-0.81% and 1.03--1.18% for LDL-C; 1.0% and 1.7% for glucose; 2.1--4.1% and 2.4--4.2% for insulin.

Participants filled in the 36-Item Short Form Health Survey (SF-36) at the time of randomization, and three, six, and 12 months later, using a web-based survey. The SF-36 is a general health related QoL measure, consisting of 36 items \[[@pone.0190662.ref033]\]. This questionnaire consists of a Physical Component Score (PCS) and a Mental Component Score (MCS), in which higher scores represents a better QoL. The SF-36 is sensitive to changes during lifestyle interventions \[[@pone.0190662.ref034]\]. The Dutch SF-36 is widely used and has demonstrated good reliability (Cronbach's α = 0.71--0.92) \[[@pone.0190662.ref035]\]. Physical activity was measured with the validated Short Questionnaire to Assess Health-enhancing physical activity (SQUASH) \[[@pone.0190662.ref036]\]. The durations of leisure time and total moderate to vigorous physical activity time per week were calculated. A Food Frequency Questionnaire was used to assess the intake of fruit, vegetables, sugary drinks, sweet snacks and savory snacks.

Statistical analysis {#sec014}
--------------------

The analyses were performed on an intention-to-treat basis: participants were analyzed in the group they were randomly assigned to, regardless of whether they completed the intervention. Mixed effects regression model analyses were constructed with a random intercept per patient for all outcomes, and with a variance component structure. Fixed effects were follow-up time, randomization group, and their interaction. The baseline measurement was included as a covariate. The dependent variable was the cardiometabolic outcome measure or QoL score. In order to analyze the odds of metabolic syndrome, a generalized linear mixed effects regression model was used. All participants with at least one measurement were included in the analyses ([Fig 1](#pone.0190662.g001){ref-type="fig"}). Data collected in pregnant participants, unknown to be pregnant at time of measurement or bloodsampling, were excluded since pregnancy is known to have substantial effects on cardiometabolic outcomes. Awareness of being pregnant may influence QoL, hence QoL data collected more than two weeks after the conception date was excluded. Since infertility treatment may also influence cardiometabolic health, an additional analysis was performed adjusted for receiving any type of infertility treatment at the time of the visit. Outcomes of the mixed effects regression model analyses are presented as estimated marginal means and 95% confidence intervals (CI). For cardiometabolic outcomes that were significantly affected by the intervention at 3 months, mediation analyses were performed using the difference in scores for physical activity and dietary outcomes between randomization and three months. All statistical analyses were performed using IBM SPSS version 24.0 (Armonk, NY, USA). The mediation analyses were performed using model 4, with 5000 bootstrapped samples for the estimation of 95% confidence intervals, of the PROCESS macro (V.2.16.3) for SPSS \[[@pone.0190662.ref037]\].

![Flowchart of participants.\
Baseline values are based on number of participants for whom BMI was available. Due to intercurrent pregnancies, or reaching the goal of the intervention prior to 24 weeks (BMI\<29 kg/m2 or \>5% weight loss) or because participants did not attend the hospital visit, the numbers of participants are decreasing over time.](pone.0190662.g001){#pone.0190662.g001}

Results {#sec015}
=======

822 women were eligible to participate, of whom 245 refused participation. 577 women were randomized ([Fig 1](#pone.0190662.g001){ref-type="fig"}). Three women withdrew informed consent after randomization, leaving a total of 289 in the intervention group and 285 women in the control group. A total of 63 of the 289 women discontinued the lifestyle intervention, due to lack of motivation (N = 40), relationship problems (N = 12), or other reasons (N = 11). [Table 1](#pone.0190662.t001){ref-type="table"} shows that the baseline characteristics of included women were similar between the two groups.

10.1371/journal.pone.0190662.t001

###### Baseline characteristics of study participants in intervention and control group.

![](pone.0190662.t001){#pone.0190662.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                   Intervention group\   Control group\
                                                                                                                                   (N = 289)             (N = 285)
  -------------------------------------------------------------------------------------------------------------------------------- --------------------- ----------------
  **Age, years, mean (SD)**                                                                                                        29.7 (4.5)            29.8 (4.6)

  **Caucasian, n (%)**                                                                                                             256 (88.6)            246 (86.3)

  **Education, n (%)**                                                                                                                                   

   - **Primary school (4--12 years)**                                                                                              17 (5.9)              10 (3.5)

   - **Secondary Education**                                                                                                       68 (23.5)             63 (22.1)

   - **Intermediate Vocational Education**                                                                                         135 (46.7)            131 (46.0)

   - **Advanced Vocational Education or University**                                                                               56 (19.4)             69 (24.2)

   - **Unknown**                                                                                                                   13 (4.5)              12 (4.2)

  **Current smoker, n (%)**                                                                                                        76 (26.7)             60 (21.1)

  **Primary infertility, n(%)**                                                                                                    183 (63.3)            186 (65.5)

  **Infertility assessment**                                                                                                                             

   - **Anovulatory infertility, n (%)**                                                                                            128 (44.3)            141(49.5)

    ◯ **PCOS diagnosed by Rotterdam 2003 criteria, n/total anovulatory (%)**(Rotterdam 2003 criteria \[[@pone.0190662.ref038]\])   97/128 (75.8)         104/141 (73.8)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BMI, Body Mass Index; PCOS, Polycystic Ovary Syndrome; Hs-CRP, High sensitive C-Reactive Protein; HDL-C, High Density Lipoprotein cholesterol; LDL-C, Low Density Lipoprotein cholesterol; HOMA-IR, Homeostasis Model of Insulin Resistance; N, number; SD, Standard deviation.

Cardiometabolic data were collected at time of randomization, as well as three months (median was 14 (interquartile range (IQR) 13--15) weeks), and six months (median was 27 (IQR 25--30) weeks) after randomization. The effects of the lifestyle intervention on cardiometabolic health, at three and six months, are shown in [Table 2](#pone.0190662.t002){ref-type="table"}.

10.1371/journal.pone.0190662.t002

###### Cardiometabolic outcomes at baseline (mean (standard error (SE))), three and six months for the intervention and control group, unless stated otherwise.

![](pone.0190662.t002){#pone.0190662.t002g}

                                           Baseline       3 months[^α^](#t002fn001){ref-type="table-fn"}   6 months[^α^](#t002fn001){ref-type="table-fn"}                                                         
  ---------------------------------------- -------------- ------------------------------------------------ ------------------------------------------------ ------------- ----------- ------------- ------------- ----------
  **Anthropometrics**                                                                                                                                                                                             
   - **Weight (kg)**                       103.6 (0.8)    103.0 (0.7)                                      99.9 (0.3)                                       102.6 (0.3)   \< 0.0001   98.6 (0.4)    102.2 (0.4)   \< 0.001
   - **BMI (kg/m**^**2**^**)**             36.1 (0.2)     36.0 (0.2)                                       34.8 (0.1)                                       35.8 (0.1)    \< 0.0001   34.3 (0.1)    35.6 (0.1)    \< 0.001
   - **Waist circumference (cm)**          108.2 (0.6)    107.9 (0.6)                                      104.6 (0.5)                                      106.3 (0.5)   0.01        102.9 (0.5)   106.3 (0.6)   \< 0.001
   - **Hip circumference (cm)**            125.0 (0.5)    125.2 (0.5)                                      121.8 (0.4)                                      124.2 (0.4)   \< 0.0001   120.4 (0.5)   124.6 (0.5)   \< 0.001
   - **Waist-hip circumference ratio**     0.87 (0.004)   0.86 (0.004)                                     0.86 (0.01)                                      0.86 (0.01)   0.975       0.86 (0.01)   0.86 (0.01)   0.960
  **Blood pressure**                                                                                                                                                                                              
   - **Systolic blood pressure (mmHg)**    126.1 (0.9)    127.0 (0.8)                                      124.2 (0.9)                                      126.3 (0.9)   0.096       121.3 (1.0)   125.4 (1.0)   0.005
   - **Diastolic blood pressure (mmHg)**   79.7 (0.6)     80.1 (0.5)                                       78.7 (0.6)                                       79.8 (0.6)    0.219       78.4 (0.7)    81.2 (0.7)    0.009
  **Biochemical measures**                                                                                                                                                                                        
   - **Hs-CRP (mg/l)**                     5.6 (0.3)      5.6 (0.3)                                        5.17 (0.38)                                      5.84 (0.40)   0.223       5.15 (0.45)   6.19 (0.47)   0.303
   - **Triglycerides (mmol/l)**            1.2 (0.05)     1.4 (0.1)                                        1.34 (0.05)                                      1.29 (0.05)   0.470       1.25 (0.06)   1.45 (0.06)   0.012
   - **Total cholesterol (mmol/l)**        4.8 (0.06)     4.8 (0.06)                                       4.79 (0.05)                                      4.79 (0.05)   0.354       4.75 (0.05)   4.90 (0.05)   0.046
   - **HDL-C (mmol/l)**                    1.2 (0.02)     1.2 (0.02)                                       1.16 (0.01)                                      1.17 (0.02)   0.624       1.19 (0.02)   1.21 (0.02)   0.346
   - **LDL-C (mmol/l)**                    3.1 (0.05)     3.1 (0.05)                                       3.02 (0.04)                                      3.12 (0.04)   0.062       3.08 (0.04)   3.14 (0.05)   0.329
   - **Glucose (mmol/l)**                  5.3 (0.04)     5.4 (0.05)                                       5.32 (0.05)                                      5.41 (0.05)   0.160       5.24 (0.05)   5.40 (0.06)   0.040
   - **Insulin (pmol/L)**                  96.5 (3.3)     103.5 (4.1)                                      89.9 (3.4)                                       104.6 (3.6)   0.003       89.4 (3.9)    95.4 (4.1)    0.297
   - **HOMA-IR**                           3.3 (0.1)      3.6 (0.2)                                        3.12 (0.13)                                      3.72 (0.14)   0.002       3.05 (0.15)   3.27 (0.16)   0.303
  **Metabolic syndrome, n (%)**            121 (52.4)     133 (58.3)                                       102 (42.6)                                       137 (57.1)    0.042       79 (33.0)     120 (49.9)    0.036

^**α**^ Values are estimated means (SE) of mixed effects regression model analyses, unless stated otherwise.

**Abbreviations:** BMI, Body Mass Index; Hs-CRP, High sensitive C-Reactive Protein; HDL-C, High Density Lipoprotein cholesterol; LDL-C, Low Density Lipoprotein cholesterol; HOMA-IR, Homeostasis Model of Insulin Resistance; N, number.

The effects of the intervention on the outcomes did not significantly change over time, as demonstrated by the fact that interaction between time and randomization group did not achieve statistical significance for any of the outcomes (data not shown). The mean weight in the intervention group over the two follow-up measurements was lower, compared to the control group (-3.1 kg 95% CI: -4.0 to -2.2 kg; P \< 0.001). BMI was lower in the intervention group compared to the control group, (-1.2 kg/m^2^ 95% CI: -1.5 to -0.8 kg/m^2^; P \< 0.001). Waist- and hip circumference were lower in the intervention group compared to the control group respectively (-2.4 cm 95% CI: -3.6 to -1.1 cm; P \< 0.001), and (-3.0 95% CI: -4.2 to -1.9 cm; P \< 0.001). Waist-hip circumference ratio did not differ between groups. Systolic blood pressure was lower in the intervention group compared to the control group (-2.8 mmHg 95% CI: -5.0 to -0.7 mmHg; P = 0.01). Diastolic blood pressure was lower in the intervention group compared to the control group (-1.7 mmHg 95% CI: -3.3 to -0.1 mmHg; P = 0.04). In the intervention group hs-CRP was lower compared to the control group, (-0.8 mg/l 95% CI: -1.7 to 0.1 mg/L), but this difference was not statistically significant (P = 0.07). Triglycerides did not differ between the control and intervention group. Total cholesterol was lower in the intervention group compared to the control group (-3.9 mg/dL 95% CI: -7.7 to 0.4 mg/dL), but this difference was not statistically significant (P = 0.09). There was no difference between the groups in HDL-C. LDL-C was, compared to the control group, lower in the intervention group (-3.9 mg/dL 95% CI: -7.7 to 0.4 mg/dL), although not statistically significant (P = 0.07). In the intervention group glucose was lower compared to the control group (-1.8 mg/dL 95% CI: -3.6 to -0.2 mg/dL; P = 0.04). Insulin was lower in the intervention group compared to the control group (-11.1 pmol/L 95% CI: -20.1 to -2.8 pmol/L; P = .01). In the intervention group HOMA-IR was lower, compared to the control group (-0.5 95% CI: -0.8 to -0.1; P = 0.01).

The prevalence of metabolic syndrome at baseline, three, and six months is shown in [Fig 2](#pone.0190662.g002){ref-type="fig"}. For women participating in the lifestyle intervention group, the odds ratio for metabolic syndrome was 0.53 (95% CI: 0.33 to 0.85; P \< 0.01) compared to women in the control group, thus the probability of having metabolic syndrome was halved in the intervention group, compared to controls. The effect of the intervention on women with PCOS at baseline was not statistically different from women without PCOS at baseline.

![Prevalence of metabolic syndrome, at baseline, three and six months, by randomization group.](pone.0190662.g002){#pone.0190662.g002}

As shown in [Fig 3](#pone.0190662.g003){ref-type="fig"}, physical QoL scores were higher in the lifestyle intervention group, compared to the control group (2.2 95% CI: 0.9 to 3.5; P = 0.001). Mental QoL scores were not different between the groups. After we adjusted the mixed effect regression models for start of infertility treatment (Ovulation induction, intra uterine insemination, in vitro fertilization treatment, or intracytoplasmic sperm injection treatment) at either three or six months, the results did not change (data not shown). The mediation analyses showed that 24% (95% CI indirect effect: -0.9163 to -0.0754) of the total effect of the intervention on fasting insulin at three months was attributable to a decrease in sugary drinks, and 12% (95% CI indirect effect: -0.6885 to -0.0302) to a decrease in savory snacks. Of the total effect of the intervention on HOMA-IR at three months, 23% (95% CI indirect effect: -0.2528 to -0.0175) was attributable to a decrease in sugary drinks, and 12% (95% CI indirect effect: -0.1860 to -0.0087) to a decrease in savory snacks. No statistically significant mediators were found for other outcomes that were improved by the intervention (results in [S2 Table](#pone.0190662.s004){ref-type="supplementary-material"}).

![Physical and mental quality of life at baseline, three, six, and 12 months, by randomization group.\
**Abbreviations:** QoL, Quality of Life; PCS, Physical Component Score; MCS, Mental Component Score. Values are presented as mean±SE.](pone.0190662.g003){#pone.0190662.g003}

Discussion {#sec016}
==========

A six month lifestyle intervention prior to infertility treatment improves cardiometabolic health in obese infertile women. Participants in the lifestyle intervention group had lower body weight, waist- and hip circumference, blood pressure, fasting glucose and insulin levels, insulin resistance, and a higher physical QoL compared to women who directly started infertility treatment. These relatively small but consistent effects on cardiometabolic factors resulted in halved odds of MetS.

The effect of the lifestyle intervention could be considered to have limited clinical relevance because of the modest effects on each of the separate outcomes. However, the effect of the intervention on the composite outcome for MetS is highly clinically relevant, since MetS leads to doubled risks of cardiovascular events and a 50% increase in all-cause mortality \[[@pone.0190662.ref008], [@pone.0190662.ref009], [@pone.0190662.ref039], [@pone.0190662.ref040]\]. Halving the odds of MetS could potentially greatly diminish the future cardiovascular risk of these women.

The intervention effects on cardiometabolic health were partly mediated by a reduction in the intake of sugary drinks and savory snacks. The reduced intake of sugary drinks improved insulin sensitivity, which can be explained by the association between sugar intake and insulin resistance \[[@pone.0190662.ref041]\]. Although increased physical activity has been associated with improved cardiometabolic outcomes, the intervention effects in the current study were not mediated by the change in physical activity \[[@pone.0190662.ref042], [@pone.0190662.ref043]\]. This is the first large multi-center RCT experimentally investigating the effects of a lifestyle intervention among obese infertile women. Previous studies in different populations have shown mixed effects of lifestyle interventions on cardiometabolic health. In contrast to our study, a recent meta-analysis including women with prior gestational diabetes showed that lifestyle interventions to prevent type 2 diabetes did not achieve weight-loss or improved fasting glucose at six months \[[@pone.0190662.ref044]\]. The reason an intervention effect was found in our study and was not found in the meta-analyses might be that the women in our trial were given an intervention that could improve their chances of reaching their primary goal; a healthy baby. Whereas, the women included in the meta-analysis did not have this strong intrinsic motivation. Another meta-analysis reported an intervention effect of -2.16 mmHg for systolic and -1.83 mmHg for diastolic blood pressure compared to usual care. Here, lifestyle intervention studies were included with a duration of at least 12 months. Participants were males and females with an average age of 53 years and a mean BMI of 30.5 kg/m2, without (pre)diabetes \[[@pone.0190662.ref045]\]. Although greater effects would be expected from lifestyle interventions of longer duration, our six month intervention led to similar lowering effects on systolic (-2.8 mmHg) and diastolic blood pressure (-1.7 mmHg). That comparable effects were achieved in only half of the time could be due to the fact that the women in our study were younger and more motivated to reduce weight in order to increase their chances on conception.

The control group also achieved some weight reduction. This might be due to the information given to all participants about the negative effects of obesity on fertility, as part of the usual care.

Approximately 35% of the participating women were diagnosed with PCOS \[[@pone.0190662.ref038]\]. PCOS often goes along with MetS, and both syndromes have a similar metabolic basis. Nevertheless, the increased cardiometabolic risks of PCOS are independent of but enhanced by adiposity \[[@pone.0190662.ref046]\]. Obese women with PCOS are more insulin resistant and at higher risk of cardiometabolic diseases including type 2 diabetes than obese women without PCOS \[[@pone.0190662.ref047], [@pone.0190662.ref048]\]. BMI is demonstrated to have a more potent extrinsic effect on insulin resistance in PCOS women compared to non-PCOS women \[[@pone.0190662.ref048]\]. Therefore, lifestyle interventions to reduce weight in obese women with PCOS seems even more important than in obese women without PCOS. In our study, similar intervention effects were found for women with as for women without PCOS.

Our finding of higher physical QoL is in concordance with previous weight loss trials \[[@pone.0190662.ref034]\]. The lack of effect of the intervention on mental QoL might be explained by the fact that women participating in this trial were infertile and their primary motivation for participating in the LIFEstyle study was to become pregnant and not to lose weight. For this reason ongoing infertility could overshadow the potential positive effect of the intervention on mental QoL \[[@pone.0190662.ref049]\].

Blinding of participants was not possible, because of the type of intervention. However, we consider it unlikely that the findings are unreliable due to bias as the biochemical outcomes were objectively measured, and the physical outcomes were assessed by research nurses not involved in the lifestyle intervention program.

The design of the current RCT has contributed to missing data ([Fig 1](#pone.0190662.g001){ref-type="fig"}), as participants who became pregnant during the first six months after randomization were excluded from further physical examination and blood sampling. Data collected during pregnancy were excluded from the statistical analyses because of the possible effects of pregnancy on the cardiometabolic health and QoL \[[@pone.0190662.ref050], [@pone.0190662.ref051]\]. Mixed effects regression model analyses were performed to deal with repeated measurements and missing data. This statistical method is able to accommodate all data available for a participant instead of excluding a participant from analysis in case of missing measurements \[[@pone.0190662.ref052]\].

Participants in the control group started infertility treatment directly, which might have affected cardiometabolic outcomes. However, after adjustment for infertility treatment, the effects of the lifestyle intervention on cardiometabolic health did not change. Hence, the effects can be attributed to the lifestyle intervention.

We have shown that a lifestyle intervention among obese infertile women improved cardiometabolic health. Based on these results obese infertile women should be informed about the positive effects of a lifestyle intervention on their cardiometabolic health and physical QoL. This may increase their intrinsic motivation to adjust lifestyle in the preconceptional period, apart from the increased chance of a natural conception and may facilitate sustained long-term lifestyle improvement \[[@pone.0190662.ref022]\]. Besides beneficial effects on health of the women, optimizing preconceptional lifestyle could lead to a healthier intrauterine environment, and improve long-term health in the offspring as well \[[@pone.0190662.ref053]--[@pone.0190662.ref055]\]. To evaluate the long-term effects of lifestyle intervention prior to infertility treatment, we are currently performing the 5--7 year follow-up of the LIFEstyle study in women and their offspring \[[@pone.0190662.ref056]\].
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